CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Siemens Healthcare Diagnostics has obtained FDA clearance for its anti-cyclic citrullinated peptide (anti-CCP) IgG assay to aid diagnosis of rheumatoid arthritis (RA). Available on the company’s Immulite 2000/2000 XPi immunoassay systems, the assay enables laboratories to integrate RA testing onto an automated, random-access analyzer.
With a clinical specificity of 97 percent, the Immulite anti-CCP IgG assay is a highly accurate diagnostic tool for fast and early RA diagnosis. The assay helps rule out other inflammatory and arthritic conditions, enabling physicians to determine an appropriate treatment path.
Siemens Healthcare Diagnostics, 847-267-5300